The webinar will feature a presentation by Key Opinion Leader (KOL) Harriet Kluger, M.D., (Yale School of Medicine) who will discuss the current treatment landscape and unmet medical need in treating patients with Post-Anti-PD-(L)1 Melanoma.

Dr. Kluger and Apexigen Chief Medical Officer Frank Hsu, M.D. will also lead a discussion on the most recent Phase 2 sotigalimab melanoma data. Sotigalimab, Apexigen’s lead immuno-oncology therapeutic, is a potentially first-in-class and best-in-class CD40 agonist, with unique epitope specificity and Fc receptor engagement for optimal therapeutic effect and tolerability.

Apexigen’s President and Chief Executive Officer, Xiaodong Yang, M.D., Ph.D., will then discuss recent pipeline advancements and provide a corporate update.

A live Q&A session will follow the formal presentations.